Literature DB >> 6846542

Alterations in renal cortical phospholipid content induced by gentamicin: time course, specificity, and subcellular localization.

T C Knauss, J M Weinberg, H D Humes.   

Abstract

Increasing evidence suggests that membrane phospholipids are a major site of interaction between gentamicin and renal tubular cells. To help assess the impact of this interaction on renal tubular cell phospholipid metabolism, renal cortical phospholipid levels were assessed serially during treatment with nephrotoxic doses of gentamicin in the rat. Within 15 h of treatment with a single 100 mg/kg dose of gentamicin, significant increases in phosphatidylinositol and phosphatidic acid occurred, and further increases in these acidic phospholipids were seen 24 h after two and four daily doses. No consistent sustained changes were observed in total phospholipid levels or in levels of other phospholipids. None of these gentamicin treatment regimens was associated with wide-spread tubular cell necrosis in the rat at the intervals studied. In contrast, during models of acute renal failure secondary to HgCl2 and glycerol, increases in phosphatidylinositol and phosphatidic acid were found only after the development of wide-spread tubular cell necrosis. Subcellular fractionation studies showed that the increase in phosphatidylinositol produced by gentamicin involved multiple cell membranes, including mitochondria, brush border membranes, endoplasmic reticulum, and lysosomes, suggesting that the effects of gentamicin on renal cortical acidic phospholipid metabolism are not limited to inhibition of intralysosomal degradative processes but, rather, occur in such fashion as to influence the phospholipid composition of multiple subcellular membranes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6846542     DOI: 10.1152/ajprenal.1983.244.5.F535

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Subcellular localization of celiptium-induced peroxidative damage in rat renal cortex.

Authors:  G Raguenez-Viotte; N Thomas; J P Fillastre
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

2.  Endotoxin-tobramycin additive toxicity on renal proximal tubular cells in culture.

Authors:  V Joly; Y Bergeron; M G Bergeron; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 3.  Intracellular mechanisms of aminoglycoside-induced cytotoxicity.

Authors:  Takatoshi Karasawa; Peter S Steyger
Journal:  Integr Biol (Camb)       Date:  2011-07-29       Impact factor: 2.192

4.  Streptomycin toxicity in primary cultures of flounder renal proximal tubule cells.

Authors:  K G Dickman; J L Renfro
Journal:  In Vitro Cell Dev Biol       Date:  1990-06

5.  Characterization of Ca2+ transport in rat renal brush-border membranes and its modulation by phosphatidic acid.

Authors:  M G Somermeyer; T C Knauss; J M Weinberg; H D Humes
Journal:  Biochem J       Date:  1983-07-15       Impact factor: 3.857

6.  Gentamicin, netilmicin, dibekacin, and amikacin nephrotoxicity and its relationship to tubular reabsorption in rabbits.

Authors:  N Brion; J Barge; I Godefroy; F Dromer; C Dubois; A Contrepois; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

7.  Decreased cellular toxicity of neomycin in a clonal cell line isolated from LLC-PK1.

Authors:  R Hori; M Okuda; Y Ohishi; M Yasuhara; K Inui; M Takano
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

8.  Calcium is a competitive inhibitor of gentamicin-renal membrane binding interactions and dietary calcium supplementation protects against gentamicin nephrotoxicity.

Authors:  H D Humes; M Sastrasinh; J M Weinberg
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

9.  Pig kidney (LLC-PK1) cell membrane fluidity during exposure to gentamicin or tobramycin.

Authors:  S J Kohlhepp; L Hou; D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.